Phase 1 ALD Clinical Trials
16 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled127 locationsNCT05006716
Recruiting
Phase 1
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Lymphoma, Non-HodgkinB-cell LymphomaWaldenstrom Macroglobulinemia+4 more
Eli Lilly and Company215 enrolled50 locationsNCT07101328
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled2 locationsNCT07249905
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1
SynKIR-310 for Relapsed/Refractory B-NHL
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+23 more
Verismo Therapeutics36 enrolled5 locationsNCT06544265
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810
Recruiting
Phase 1
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Mantle Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Stanford University148 enrolled1 locationNCT06340737
Recruiting
Phase 1Phase 2
Autologous Adipose Cells Therapy
Hair ThinningHair Loss/BaldnessWrinkle Appearance+5 more
CERM INC.40 enrolled2 locationsNCT06869252
Recruiting
Phase 1Phase 2
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
Primary AldosteronismPrimary Aldosteronism Due to Aldosterone Producing Adenoma
Peking Union Medical College Hospital150 enrolled1 locationNCT06773663
Recruiting
Phase 1Phase 2
Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Primary Aldosteronism
University Medical Center Groningen12 enrolled1 locationNCT06616142